Coagulation factor IXa-VIIIa complex (FIXa-FVIIIa)

The intrinsic tenase complex is a multi-component enzyme assembly that forms on the procoagulant phospholipid surface of activated platelets, primarily consisting of the serine protease Factor IXa and its essential cofactor, Factor VIIIa [1, 2]. This complex plays a vital role in the amplification phase of the blood coagulation cascade by catalyzing the conversion of Factor X to Factor Xa, a process that occurs independently of the Tissue Factor (TF) pathway [1, 3]. The assembly of this complex on the platelet surface, facilitated by calcium ions, increases the efficiency of Factor X activation by several orders of magnitude compared to the action of Factor IXa alone [2, 4]. Deficiencies in the protein components of this complex are the underlying cause of Hemophilia A (Factor VIII deficiency) and Hemophilia B (Factor IX deficiency), leading to impaired fibrin clot formation and significant bleeding risk [3, 4]. Conversely, the complex is a target for antithrombotic therapy; for instance, heparins act by accelerating the inhibition of Factor IXa by antithrombin III, while novel bispecific antibodies like emicizumab mimic the function of Factor VIIIa to restore Factor X activation in hemophilic patients [5, 6]. Monitoring the activity of this complex is typically achieved through the activated partial thromboplastin time (aPTT) assay and specific factor activity measurements [2].

Other names

Intrinsic tenase complexTenase complexFactor IXa-Factor VIIIa complexPlatelet-bound tenaseActivated platelet surface leading to TF-independent Factor X activation

The complex functions as a serine protease assembly that proteolytically activates Factor X. Drugs like emicizumab bridge FIXa and FX to bypass FVIIIa deficiency, while anticoagulants like heparin enhance the inhibition of the FIXa subunit by antithrombin III.